Characteristics of patients initiating teriparatide for the treatment of osteoporosis

被引:14
|
作者
Foster, S. A. [1 ]
Foley, K. A. [2 ]
Meadows, E. S. [1 ]
Johnston, J. A. [1 ]
Wang, S. [2 ]
Pohl, G. M. [1 ]
Long, S. R. [2 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] Thomson Medstat, Ann Arbor, MI USA
关键词
bisphosphonates; demographics; osteoporosis; teriparatide; treatment;
D O I
10.1007/s00198-007-0455-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The demographic and clinical characteristics of patients initiating teriparatide were compared with those of patients initiating bisphosphonates for the treatment of osteoporosis. In these samples of commercially insured, Medicare, and Medicaid patients, patients initiating teriparatide were older, in poorer health, and appeared to have more severe osteoporosis than patients initiating bisphosphonates. Introduction The demographic and clinical characteristics of patients initiating teriparatide are compared with those of patients initiating bisphosphonates. Methods Beneficiaries (45 years and older) with at least one claim for teriparatide or a bisphosphonate from 2003 to 2005 and continuous enrollment in the previous 12 months and subsequent 6 months were identified from commercial, Medicare, and Medicaid administrative claims databases. Patients initiating teriparatide (commercial/Medicare (N=2,218); Medicaid (N=824)) were compared to patients initiating bisphosphonates (commercial/Medicare (N=97,570); Medicaid (N=77,526)) in terms of age, provider specialty, comorbidities, prior use of osteoporosis medications, fractures, BMD screening, health status, and resource utilization. Results Teriparatide patients were older and in poorer health than bisphosphonate patients. Approximately 38% of teriparatide patients in both groups had fractured in the pre-period compared to 16% of commercial/Medicare and 15% of Medicaid bisphosphonate patients. Teriparatide patients were more likely to have used osteoporosis medications in the pre-period (79.9% versus 32.1% (commercial/Medicare); 82.2% versus 19.6% (Medicaid)). Conclusions In these samples of patients, those initiating teriparatide differed from those initiating bisphosphonates. Teriparatide patients were older, in poorer health, and appeared to have more severe osteoporosis than bisphosphonate patients. Comparisons of treatment outcomes should take these differences in patient characteristics into consideration.
引用
收藏
页码:373 / 377
页数:5
相关论文
共 50 条
  • [21] TERIPARATIDE IN PATIENTS WITH OSTEOPOROSIS - OUR EXPERIENCE
    Nikolic, Aleksandra Karadzov
    Pilipovic, Nada
    Brankovic, Slobodan
    Novkovic, Snezana
    Basaric, Milica
    Pasalic, Katarina Simic
    [J]. OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S297 - S297
  • [22] THE EFFECT OF BISPHOSPHONATE USE PRIOR TO WEEKLY TERIPARATIDE TREATMENT IN OSTEOPOROSIS PATIENTS
    Yokozeki, D. R.
    Murata, D. R.
    Koyama, D. R.
    Inoue, D. R.
    Miyagi, D. R.
    Shirasawa, D. R.
    Tajima, D. R.
    Kawakubo, D. R.
    Uekusa, D. R.
    Saito, D. R.
    Tsuchiya, D. R.
    Mimura, D. R.
    Yoneda, D. R.
    Naruse, D. R.
    Uchida, D. R.
    Takaso, D. R.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S201 - S201
  • [23] THE COMPARATION OF EFFICACY OF TREATMENT WITH TERIPARATIDE IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS AND GLUCOCORTICOID INDUCED OSTEOPOROSIS IN COMMON POPULATION
    Ruzickova, O. R.
    Tomasova, J. T.
    Sokalska, M. S.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S481 - S483
  • [24] Efficacy of raloxifene and teriparatide in patients with osteoporosis
    Marie Lofthouse
    [J]. Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 (4): : 182 - 183
  • [25] Treatment of Severe Osteoporosis in Youngs with Teriparatide And Denosumab
    Quesada Gomez, Jose Manuel
    Munoz, Concepcion
    Angeles Galvez, Maria
    Diez-Perez, Adolfo
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S323 - S323
  • [26] Transient osteoporosis of the hip: successful treatment with teriparatide
    Gianluigi Fabbriciani
    Matteo Pirro
    Maria Rosaria Manfredelli
    Massimo Bianchi
    Silvio Sivolella
    Anna Maria Scarponi
    Elmo Mannarino
    [J]. Rheumatology International, 2012, 32 : 1367 - 1370
  • [27] Impressive results of teriparatide treatment of postgastrectomy osteoporosis
    Bacun, Tatjana
    Kibel, Aleksandar
    Pavic, Roman
    [J]. MEDICINSKI GLASNIK, 2011, 8 (02) : 305 - 308
  • [28] Teriparatide - The molecular and clinical profile in osteoporosis treatment
    Jakob, Franz
    Mueller-Deubert, Sigrid
    Ebert, Regina
    [J]. OSTEOLOGIE, 2019, 28 (01) : 20 - 27
  • [29] Clinical experience with teriparatide for the treatment of osteoporosis.
    Bachrach, L.
    Camacho, P. M.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S296 - S296
  • [30] Analysis of daily teriparatide treatment for osteoporosis in men
    Niimi, R.
    Kono, T.
    Nishihara, A.
    Hasegawa, M.
    Matsumine, A.
    Kono, T.
    Sudo, A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2015, 26 (04) : 1303 - 1309